Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors

[1]  S. Gui,et al.  Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence , 2021, Neurosurgical Review.

[2]  Michael Lim,et al.  Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence , 2021, Cancers.

[3]  X. Hua,et al.  Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival , 2021, Nature Communications.

[4]  K. Yamaguchi,et al.  Role of Tumor Mutation Burden Analysis in Detecting Lynch Syndrome in Precision Medicine: Analysis of 2,501 Japanese Cancer Patients , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[5]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[6]  J. Barnholtz-Sloan,et al.  Descriptive epidemiology of chordomas in the United States , 2020, Journal of Neuro-Oncology.

[7]  F. Soylemezoğlu,et al.  Poorly differentiated chordoma: review of 53 cases , 2019, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[8]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[9]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[10]  G. Nielsen,et al.  Clinicopathologic characteristics of poorly differentiated chordoma , 2018, Modern Pathology.

[11]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Landis,et al.  First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies , 2017, Oncoimmunology.

[13]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[14]  M. Irie.  Brain Tumor Registry of Japan (2005–2008) , 2017, Neurologia medico-chirurgica.

[15]  K. Schaller,et al.  Incidence and relative survival of chordomas , 2013, Cancer.

[16]  H. Vasen.  Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer) * , 2007, Alimentary pharmacology & therapeutics.

[17]  A. Samii,et al.  Chordomas of the skull base: surgical management and outcome. , 2007, Journal of neurosurgery.

[18]  W. Weber,et al.  Case Report: Familial Gastric Cancer and Chordoma in the Same Family , 2005, Hereditary Cancer in Clinical Practice.